iNFixion Bioscience, Inc.

Biotechnology ResearchCalifornia, United States2-10 Employees

iNFixion Bioscience, Inc. is a biotechnology research company focused on developing drug therapies to treat and prevent the progression of Neurofibromatosis Type 1 (NF1), a rare genetic disorder affecting approximately 2.5 million people worldwide. The company aims to address the root cause by boosting the body's ability to produce and maintain functional Neurofibromin protein, which underpins NF1-related symptoms. Its antisense oligonucleotide therapy is being developed to increase NF1 protein expression, targeting the underlying mechanism driving NF1.

Based in San Diego, California, the firm operates with a small team dedicated to advancing this mechanism-based approach for patients living with NF1 and the clinicians who treat them. Recent activity includes partnerships and engagement with the NF1 research community, such as a collaboration with the Gilbert Family Foundation in 2025 and participation in NF-focused conferences.

Sign up for free to view info

Email Format Employee directory